FDA likely to further restrict erythropoietin use for cancer patients.
Fox
Jeffrey L
JL
D017277:Drug Approval / Q000458:organization & administration*; D004921:Erythropoietin / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*
D004921:Erythropoietin